Capricor Therapeutics (CAPR) Stock Price & Analysis

CAPR$9.53-0.71 -6.93%
BiotechnologyValue StockGrowth Stock
Compare
Market cap$551.90MEnterprise value$591.32MRevenue (TTM)$0Market position—

Score

68
Bullish
Value
61
Quality
42
Growth
100

AI Analysis

Snapshot

Capricor Therapeutics doesn’t screen as a clean setup today — Stocklytics 68/100 leaves more to prove. Under the hood: revenue compounding ~258% annually over recent years.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

61
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

100
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

42
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Capricor Therapeutics, Inc. (CAPR) last printed $9.53. Equity value is $551.90M. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$3.19M$2.67M$1.67M$1.01M$310,250.00$244,898.00$2.55M$25.18M$22.27M$0.00

About

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics (CAPR) Stock Price & Analysis

CAPR price $9.53 -0.71 -6.93%

Ticker
CAPR
Price
$9.53
Change
-0.71 -6.93%
Market cap
$551.90M
Forward P/E
28.64
Dividend yield
0.00%
Beta
0.53
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
68
Value
61
Quality
42
Growth
100

Stocklytics score rationale: value 61, quality 42, growth 100.

Insights · Forecast · Financials · Learn

Stocklytics home · Screener